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Allogeneic blood transfusion is emerging as a potent risk factor for several complications 
commonly seen in hospitalized patients and as 
an independent predictor of, or contributor to, 
worse patient outcomes.1 Some of the risks and 
complications historically linked with blood 
transfusions (e.g. transfusion reactions and trans-
mission of pathogens) have been largely miti-
gated through advancements in blood banking 
whereas some others (e.g. immunomodulation 
and transfusion-related acute lung injury) 2 ap-
pear to have more subtle aetiologies and are more 
difficult to tackle. Consequently, the era of think-
ing of blood transfusion as a vitalizing treatment 
to improve patients’ conditions and accelerate 
their recovery has now been superseded by judi-
cious consideration of allogeneic blood transfu-
sions when other, less-risky modalities are not 
available. Despite current evidence indicates that 
a significant number of the patients who are be-
ing transfused, even those in the operatory thea-
tres and intensive care units (ICU), may not be 
having substantial benefits from that treatment, 
the overall use of allogeneic red blood cell (RBC) 
transfusions in clinical practice remains rela-
tively high with wide variations among centres 
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and practitioners.1, 3 Finally, pressure is increas-
ing from staggering associated costs and limited 
supplies. Patient blood management (PBM) is an 
evidence-based, multidisciplinary, multimodal, 
and patient-tailored approach aimed at reducing 
or eliminating the need for allogeneic transfusion 
by managing anaemia, perioperative blood con-
servation, surgical haemostasis, and blood as well 
as plasma-derived medicinal product use.4 From 
this point of view, the reduction of allogeneic 
blood usage is not an end in itself but a tool to 
achieve better patient clinical outcome. In this 
article we aim to report the state of the art about 
PBM through an analysis of the most relevant 
recent research. We hope that the results will 
contribute to optimizing the use of blood, which 
continues to be one of the most relevant resourc-
es in caring surgical and critically ill patients.
What is patient blood 
management: the 3 pillars
The Society for the Advancement of Blood 
Management (SABM) (a nonprofit multipro-
fessional and multidisciplinary international 
society collaborating with governmental or-
ganisations, regulatory agencies, and corporate 
partners to bring together resources, knowledge, 
and funding to pursue its mission, namely to 
improve health outcomes by advancing compre-
hensive PBM practices, promoting innovative 
research, and providing quality professional and 
public education) defined PBM as “the timely 
application of evidence-based medical and surgi-
cal concepts designed to maintain haemoglobin 
concentration, optimise haemostasis and mini-
mise blood loss in an effort to improve patient 
outcome”.4 Therefore, the primary goal and 
interest of PBM is the improvement of patient 
clinical outcome while all other issues and con-
siderations – including the usage of allogeneic 
transfusions – are secondary. PBM pursues bet-
ter patient outcomes (and cost reduction) rely-
ing “on a patient’s own blood rather than on 
donor blood” and “goes beyond the concept of 
appropriate use of blood products, because it 
pre-empts and significantly reduces the resort to 
transfusions by addressing modifiable risk fac-
tors that may result in transfusion long before a 
transfusion may even be considered”.5 The afore-
mentioned objective(s) can be reached through 
the so-called three pillars of PBM that are strate-
gic to implementing the paradigm-shift of PBM 
(which is centred on the patient and not on the 
blood-component) (Table I): 1) optimizing the 
patient’s erythropoiesis; 2) minimizing bleeding; 
and 3) harnessing and optimising the patient-
specific physiological reserve of anemia.5
Actually, the global management (and preven-
tion) of anemia starts from the first pillar but 
permeates the whole three-pillar approach of 
PBM through a multifaceted armamentarium 
of pharmacological and non-pharmacological 
techniques and strategies.6 Anemia is defined by 
the normal range of hemoglobin for a healthy 
population and the range of its prevalence varies 
widely among studies according to the definition 
adopted with the lowest reported prevalence ob-
viously found in studies using the most stringent 
criterion. Although there is no definitive agree-
ment on the definition of anemia, one of the 
most commonly used definitions to detect pre-
operative anemia is the one used by the World 
Health Organization: children 0.50-4.99 years: 
11 g/dL; children 5.00-11.99 years: 11.5 g/dL; 
children 12.00-14.99 years: 12 g/dL; pregnant 
women: 11 g/dL; non-pregnant women (≥15.00 
years): 12 g/dL; men (≥15.00 years): 13 g/dL. 
It is worth pointing out that the above haemo-
globin concentrations are not relevant thresholds 
by which to understand either critical bleeding 
or the need for blood transfusion.7
Preoperative anemia in surgical patients has 
a widely ranging prevalence, namely from 5% 
(geriatric patients with hip fracture) to 78.5% 
(patients with Dukes stage D colon cancer).8 In 
orthopaedic patients, candidates for elective to-
tal hip and total knee arthroplasty or hip fracture 
surgery, it ranges from 24±9% to 44±9%, respec-
tively. The prevalence of haematinic deficiencies 
ranges from 23% to 70% for iron (defined by 
either hypochromic [mean corpuscolar hemo-
globin <27 pg] microcytic anaemia or serum-
soluble transferring receptor level <1.76 mg/L),9 
is around 12% for vitamin B12 (defined by serum 
concentration <270 pg/mL [200 pmol/L]),10 and 
is 3% for folate [defined by serum concentration 
<3 ng/mL [5 nmol/L]).10
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least 30 days before the scheduled surgical proce-
dure to allow the implementation of appropriate 
treatment, if available.6, 14
However, also up to 74% of patients with 
normal hemoglobin levels on hospital admission 
subsequently can develop hospital-acquired ane-
mia, which is associated with increased mortal-
ity and resource utilization 15 as well as higher 
morbidity.14 Postoperative anaemia prevalence 
Several recent studies exploring the relation-
ship between pre-operative anaemia and out-
come highlighted a link with higher postop-
erative mortality and morbidity as well as an 
increased risk of receiving allogeneic transfu-
sions.11-13 Therefore, according to PBM, anemia 
is a contraindication for major elective surgery 
at high risk of bleeding and/or consistent an-
ticipated blood loss and it should be detected at 
Table I.—The three pillars of patient blood management.4
Stage/pillar
Pillar 1
Optimise erythropoiesis
Pillar 2
Minimise bleeding  
and blood loss
Pillar 3
Harness and optimise  
physiological reserve of anaemia
Preoperative
Detect anaemia Identify and manage bleeding risk Assess/optimise patient’s physiological 
reserve and risk factors
Identify underlying disorder(s) 
causing anaemia
Minimising iatrogenic blood loss Compare estimated blood loss with 
patient-specific tolerable blood loss
Manage disorder(s) Procedure planning and rehearsal Formulate patient-specific 
management plan using 
appropriate blood conservation 
modalities to minimise blood loss, 
optimise red cell mass and manage 
anaemia
Refer for further evaluation if 
necessary
Preoperative autologous blood 
donation (only in selected cases)
Restrictive transfusion thresholds
Treat suboptimal iron stores/
iron deficiency/anaemia of 
chronic disease/iron-restricted 
erythropoiesis
Treat other haematinic deficiencies
Intraoperative
Timing surgery with haematological 
optimisation
Meticulous haemostasis and surgical 
techniques
Optimise cardiac output
Blood-sparing surgical techniques Optimise ventilation and oxygenation
Anaesthetic blood conserving 
strategies
Restrictive transfusion thresholds
Autologous blood options
Pharmacological/haemostatic agents
Point-of-care testing
Postoperative
Stimulate erythropoiesis Vigilant monitoring and 
management of post-operative 
bleeding
Optimise anaemia reserve
Be aware of drug interactions that 
can increase anaemia
Avoid secondary haemorrhage Maximise oxygen delivery
Rapid warming/maintaining 
normothermia (unless 
hypothermia specifically 
indicated)
Minimise oxygen consumption
Autologous blood salvage if 
appropriate
Avoid/treat infections promptly
Minimising iatrogenic blood loss 
and be aware of adverse effects of 
medication
Restrictive transfusion thresholds
Haemostasis/anticoagulation 
management
Prophylaxis of upper gastrointestinal 
haemorrhage
Avoid/treat infections promptly
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In addition, bleeding can also be reduced by a 
joint, coordinated and patient-tailored usage of 
several pharmacological and non-pharmacolog-
ical techniques and strategies (e.g. less invasive 
surgery and computer-assisted surgery, neurax-
ial anesthesia, patient positioning, maintenance 
of normothermia, controlled hypotension - de-
fined as a reduction of the systolic blood pressure 
to 80-90 mm Hg, a reduction of mean arterial 
pressure to 50-65 mmHg or a 30% reduction 
of its baseline value 24, point-of-care coagulation 
testing, topical hemostatic agents - such as fi-
brin sealant - and hemostatic drugs - tranexam-
ic acid) although, at present, different level of 
evidence supports their efficacy.17 Furthermore, 
hyperoxic ventilation in combination with nor-
movolemic hemodilution might be considered 
a useful method for reducing allogeneic trans-
fusion support during surgical bleeding,15 or at 
least for postponing transfusion until bleeding 
can be controlled but keeping in mind that it 
may have a role only in short term maintenance 
of tissue oxygenation.25
The third PBM pillar encompasses the pr-
eoperative preparation of the patient, the in-
traoperative optimisation of oxygen transport 
and tissue oxygenation, the maintenance of the 
postoperative balance of oxygen delivery and 
oxygen consumption, and the use of restrictive 
transfusion thresholds.17 To this regard, pooled 
data from randomized trials show that RBC 
transfusions can increase in-hospital mortality, 
total mortality, rebleeding, acute coronary syn-
drome, pulmonary oedema, and bacterial infec-
tions.26 On the other hand, a growing body of 
evidence from clinical trials, with few dissenting 
studies 27 indicates that a restrictive transfusion 
strategy, namely administering RBCs once the 
hemoglobin falls below either 7 or 8 g/dL is safe 
in most clinical settings. A 2011 Cochrane re-
view evaluating transfusion trigger in a variety 
of populations found that a haemoglobin trans-
fusion threshold of 7 or 8 g/dL compared with 
a higher haemoglobin transfusion threshold 
(10 g/dL) results in: 1) a reduction of the risk 
of receiving a RBC transfusion by 39% (risk ra-
tio [RR], 0.61; 95% confidence interval [CI], 
0.52-0.72) that equates to an average absolute 
risk reduction of 34% (95% CI, 24-45%); 2) 
in elective total hip or knee arthroplasty and in 
hip fracture surgery is even higher (51% and 
87±10%, respectively) 9 and can even be as high 
as 90% in surgical patients.8 It is mainly related 
to peri-operative bleeding but can be worsened 
by repeated phlebotomy for diagnostic testing 
as well as by blunted erythropoiesis caused by 
surgery-induced inflammatory responses, espe-
cially through decreased iron availability (i.e. 
hepcidin-dependent down-regulation of intesti-
nal absorption and impaired mobilization from 
body stores).16
The second PBM pillar includes all the strate-
gies to minimise bleeding and save the patient’s 
own blood.17 The first step is the thorough pre-
operative assessment of the patient aimed at iden-
tifying and managing the bleeding risk and any 
potential risk factor for iatrogenic blood loss.14 
Singbartl et al. recently ranked the effectiveness 
of autologous blood conservation measures and 
very elegantly confirmed that intraoperative 
blood salvage is the most efficacious and effec-
tive autologous blood conservation measure.18 
As far as post-operative blood salvage is con-
cerned, while topical tranexamic acid can be 
recommended with less strength to contain the 
transfusion requirements in in total hip and total 
knee arthroplasty,19 its systemic use is gaining an 
ever-increasing evidence of safety and efficacy in 
significantly reducing the amount of blood loss.20
Therefore, the ever-increasing use of peri-
operative intravenous tranexamic acid is re-
ally questioning the usefulness of postoperative 
blood salvage as an autologous blood conserva-
tion measure in orthopaedic surgery,21 especially 
if the post-operative collection devices are in-
discriminately used without identifying those 
patients at real risk of significant early postop-
erative blood loss and those who, being really 
anaemic, would actually benefit from shed blood 
transfusion therapy.22, 23 Recovery and reinfu-
sion of blood from surgical drains is a very com-
monly used technique exploiting devices whose 
primary function is to act as a reservoir for the 
shed blood. When adequate amounts of blood 
are collected, the system is flipped over and 
plugged into an intravenous line. This procedure 
has earned these devices the nickname of “flip-
n-drip” systems. 21
              COPYRIGHT© 2015 EDIZIONI MINERVA MEDICA 
Th
is
 d
oc
um
en
t i
s 
pr
ot
ec
te
d 
by
 in
te
rn
a
tio
na
l c
op
yr
ig
ht
 la
w
s.
N
o 
ad
di
tio
na
l r
ep
ro
du
ct
io
n 
is 
au
th
or
ize
d.
It 
is
 p
er
m
itt
ed
 fo
r 
pe
rs
on
al
 u
se
 to
 d
ow
n
lo
ad
 a
nd
 s
av
e
 o
n
ly 
on
e 
file
 a
nd
 p
rin
t o
nl
y 
on
e 
co
py
 o
f t
hi
s 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 m
ak
e
 a
dd
itio
na
l c
op
ie
s
(ei
the
r s
po
rad
ica
lly
 o
r s
ys
te
m
at
ica
lly
,
 
e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c) 
of 
the
 A
rtic
le
 fo
r 
a
ny
 p
ur
po
se
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 d
ist
rib
u
te
 th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cl
e 
th
ro
ug
h 
on
lin
e 
in
te
rn
e
t a
nd
/o
r i
nt
ra
n
e
t f
ile
 s
ha
rin
g 
sy
st
em
s,
 
e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
m
e
a
n
s 
w
hi
ch
 m
ay
 a
llo
w
 a
cc
e
ss
 to
 th
e 
Ar
tic
le
.
Th
e 
us
e 
of
 a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cl
e 
fo
r 
a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
.T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e
 w
o
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
.T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r 
pe
rs
on
al
 o
r c
om
m
er
cia
l u
se
 is
n
o
t p
er
m
itt
ed
.I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r,
 
ov
e
rla
y, 
o
bs
cu
re
,
 
bl
oc
k,
 o
r c
ha
ng
e 
an
y 
co
py
rig
ht
 n
ot
ice
s 
or
 te
rm
s 
o
f u
se
 w
hi
ch
 th
e 
Pu
bl
is
he
r m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 fr
a
m
e
 o
r 
u
se
 fr
a
m
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
a
de
m
ar
k,
 lo
go
,
o
r 
o
th
er
 p
ro
pr
ie
ta
ry
 in
fo
rm
a
tio
n 
of
 th
e 
Pu
bl
is
he
r.
PATIENT BLOOD MANAGEMENT LIUMBRUNO
Vol. 81 - No. 10 MINERVA ANESTESIOLOGICA 1131
than a more restrictive strategy (i.e. transfusing 
for symptoms from anemia or for a haemoglobin 
<8 g/dL) thus supporting the feasibility of and 
the need for a definitive trial in this specific clin-
ical setting. Interestingly, the same higher blood 
transfusion threshold (hemoglobin >10 g/dL) 
was not able to prevent new or worsening de-
lirium symptoms in postoperative hip-fracture 
older adult patients.30 Accordingly, a compari-
son of more recent transfusion guidelines shows 
that they generally agree that hemoglobin alone 
is not a very informative parameter to use as a 
basis for transfusion decision and transfusion is 
not beneficial when the hemoglobin concentra-
tion is >10 g/dL, but is usually indicated when 
its concentration is <6 g/dL and, for patients 
with Hb 6-10 g/dL, acknowledge the necessity 
of individualizing the decision to initiate trans-
fusion by incorporating patient-related factors 
such as age, comorbidities, and risk or evidence 
of ischaemia as well as amount and rate of blood 
loss.31
In addition, as new convincing evidence re-
cently showed, a restrictive transfusion approach 
to RBC transfusion may also have the additional 
benefit of reducing the incidence of health-care-
associated infection.32 Therefore, the implemen-
tation of restrictive strategies among hospital-
ised patients does seem to be safe and should 
be the cornerstone of any blood conservation 
programme,33 which, in stable, non-bleeding 
patients with anaemia should also be based on 
a single-unit-transfusion ordering policy (fol-
lowed by clinical and laboratory reassessment to 
determine the need for further transfusion) that 
is supported by a growing evidence.34-36
Although the rational use of blood products 
is not only driven by rationalization but also by 
the wish to improve perioperative patient care, 
PBM also derives from an increasing awareness 
that in the future blood supply shortages could 
arise because of an aging population 37 and also 
from an economic-financial rationale 31 stem-
ming from a growing awareness of the high 
direct and indirect transfusion therapy costs.38 
This will undoubtedly help the promotion of 
PBM as a cost-effective strategy, both in the in-
terest of patients and health-care social (sustain-
able) costs.39
fewer blood transfusions (mean difference, 1.19 
units per patient; 95% CI, 0.53-1.85 units); 3) 
a statistically significant reduction of in-hospital 
mortality (RR, 0.77; 95% CI, 0.62-0.95) but 
not 30-day mortality (RR, 0.85; 95% CI, 0.70-
1.03). The use of restrictive strategies did not 
cause, cardiac morbidity, impaired functional 
recovery, or prolonged hospital length of stay 
(LOS).
A recent meta-analysis and systematic re-
view by Salpeter et al.26 focused on the question 
whether the lower 7-g/dL threshold is superior to 
the higher threshold of 8 g/dL and showed that 
in patients with critical illness or bleed, restrict-
ing blood transfusions by using a haemoglobin 
trigger of <7 g/dL significantly reduces cardiac 
events (RR, 0.44; CI, 0.22-0.89), re-bleeding 
(RR, 0.64; CI, 0.45-0.90), bacterial infections 
(RR, 0.86; CI, 0.73-1.00), in-hospital mortality 
(RR, 0.74; CI, 0.60-0.92), and total mortality 
(RR, 0.80; CI, 0.65-0.98). The number needed 
to treat with a restrictive strategy to prevent 1 
death is 33. However, an important limitation 
of prospectively randomized clinical trials is that 
patients who are both eligible and who agree 
to participate in the study might not be repre-
sentative of all patients in these clinical settings. 
The impact of RBC transfusion reduction on 
mortality in a diverse inpatient population has 
been recently addressed in a real-world setting 
by Roubinian et al. who analysed a large health 
care database including more than 200,000 pa-
tients.28 They showed that a greater than 20% 
reduction in RBC use over 3 years and a con-
current more restrictive transfusion practice (i.e. 
a statistically significant drop in median pre-
transfusion haemoglobin level from 8.1 g/dL to 
7.5 g/dL) over the same period did not affect 
adjusted and unadjusted mortality rates.
A recent pilot trial addressed even the contro-
versial issue of liberal versus restrictive transfu-
sion thresholds for patients with symptomatic 
coronary artery disease.29 The trial recruited pa-
tients with acute coronary syndrome or stable 
angina undergoing cardiac catheterization and 
a hemoglobin <10 g/dL and showed that the 
liberal transfusion strategy (i.e. raising the he-
moglobin level ≥10 g/dL) was associated with a 
trend for fewer major cardiac events and deaths 
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9.9 vs. 9.5 g/dL, P<0.001). However, no differ-
ences in between in-hospital or 30-day mortality 
(1% vs. 1%, P=1; 1% vs. 2%, P=0.25, respec-
tively), re-operation for bleeding (4% vs. 4%, 
P=0.89), or other post-operative outcomes such 
as peri-operative myocardial infarction (<1% vs. 
0%, P=0.47), atrial fibrillation (23% vs. 23%, 
P=0.82), prolonged (>24 hours) ventilator sup-
port (9% vs. 10%, p: 0.52), wound infections (< 
1% vs. 1%, P=0.53), sepsis (1% vs. 1%, P=0.74) 
renal insufficiency needing haemodialysis (2% 
vs. 1%, P=0.53), transient ischaemic attack (1% 
vs. 1%, P=1), multiorgan system failure (<1% vs. 
0%, P=0.47) were detected between the control 
and study group. Masud et al. implemented a 
multidisciplinary team-driven PBM programme 
and reported a reduction in post-operative blood 
product use among coronary artery bypass graft 
patients (a 14.3% decrease in the first year and 
30.6% from 2006 to 2008), an 18.2% reduc-
tion of blood product volume used in the entire 
cardiovascular intensive care unit, and an esti-
mated savings of more than $ 1 million, with no 
additional harm to patients and a trend toward 
better clinical outcomes [i.e. expected operative 
mortality index (from 1.41 to 1.29), infection 
rates (including the rate of ventilator-associated 
pneumonia), and cardiovascular intensive care 
unit average LOS (from 4.04 days to 3.83 days)] 
before and after the initiative.45
Recently, in Switzerland, a before and after 
study in elective orthopaedic surgery was carried 
out to investigate the impact of the introduc-
tion of a PBM programme, which resulted in: 
1) a significantly lower incidence of immediate 
preoperative anemia in hip and knee surgery 
(from 17.6 % to 12.9 % [P<0.001] and from 
15.5% to 7.8% [P<0.001], respectively), while 
in spine surgery its prevalence remained un-
changed (12.6% vs. 10.3%, P=0.113); ii) an un-
changed RBC mass loss in hip surgery (626±434 
vs. 635±450 mL, P=0.974) and a significantly 
RBC mass loss reduction in knee and spine sur-
gery (from 573±355 to 476±365 mL [P<0.001] 
and from 551±421 to 404±337 mL [P<0.001], 
respectively); 3) a significantly lower transfu-
sion rate (from 21.8% to 15.7% [P<0.001] in 
hip surgery; from 19.3% to 4.9% [P<0.001] in 
knee surgery, and from 18.6 to 8.6% [P<0.001] 
Patient blood management: 
the available evidence
In 1991, one of the first blood conservation 
strategies in cardiac surgery was developed by 
Ovrum and co-workers who managed to avoid 
allogeneic blood transfusion in 484 out of 500 
patients (96.8%) through the simple (and cost-
effective) intra- and post-operative-re-transfu-
sion of autologous (shed) blood.40 From the ear-
ly 90s on, the evaluation of the role that several 
single strategies included in PBM programmes 
exerted on clinical and surrogate outcomes has 
produced a wealth of data showing a reduced use 
of blood products and the cost-effectiveness of 
the programmes, which have been mainly ap-
plied in cardiac, major orthopedic, and trans-
plantation surgery as well as in trauma centres.41 
This article will only strive to focus on the lim-
ited and recently emerging data on the impact of 
PBM programmes as a whole, being aware that 
the eagerness of the scientific community who is 
longing for more outcome data will probably be 
satisfied in the next few years.42
In 2001, Van der Linden et al. reported a safe 
and cost-effective 53% decrease in RBC usage 
and a 46% decrease in the number of elective-
cardiac-surgery patients receiving any blood 
products, without any significant difference in 
post-operative haemoglobin.43 In addition, con-
trol and study groups showed similar in-hospi-
tal mortality (4.7% vs. 3.8%, p: 0.59), inten-
sive care unit (2.6 ± 4.2 days vs. 2.7±3.6 days, 
p: 0.97) and hospital LOS (10.6±8.4 days vs. 
10.3±6.2 days, p: 0.64). Postoperative complica-
tion rate was also comparable (acute myocardial 
infarction: 7.8% vs. 9.2%, P=0.52; respiratory 
problems: 14.3% vs. 12.1%, p: 0.41; wound in-
fections: 2.5% vs. 3.2%, P=0.61; neurologic def-
icit: 1.9% vs. 1.6%, P=0.34; renal insufficiency 
needing haemodialysis: 4.4% vs. 3.2%, P=0.46). 
Still in cardiac surgery, a more recent study de-
termined the effects of a PBM programme based 
on algorithm-driven transfusion decisions ex-
ploiting lower transfusion triggers, point-of-care 
testing, and blood-saving measures.44 The total 
blood product use was reduced by 40% and con-
trol patients had a slightly higher pre-discharge 
hemoglobin level than study patients (median: 
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arena is at present largely dominated by observa-
tional studies, which through an ever-increasing 
wealth of data show that the implementation of 
this patient-centric-transfusion-medicine tool 
reduces blood transfusions and hospital costs 
as well as transfusion-related morbidities and 
mortality but further research on the impact of 
PBM strategies on (long-term) patient outcomes 
is needed. 49
Being aware that designing and carrying out a 
PBM randomised trial is extremely challenging, 
Gross proposed to measure the impact of multi-
modal PBM strategies on outcomes through reg-
istries of treated patients rather than randomised 
controlled trials since the former more closely 
resemble those patients we come across in daily 
clinical practice.42
PBM around the world and in Italy
In 2010, the World Health Organization 
(WHO), with the resolution WHA63.12, urged 
all member states to implement PBM.50
However, at the moment, Australia is the 
first example of a national public health system 
thoroughly compliant with the WHO request. 
In fact, the National Blood Authority developed 
comprehensive six-module-evidence-based PBM 
national guidelines.51 This national policy exert-
ed a major influence in the adoption of PBM by 
several centres.52
In the USA, PBM has attracted the attention 
of the Association for Advancing Transfusions 
and Cellular Therapies (AABB), the SABM and 
the Joint Commission.53, 54 At present, in this 
country, PBM programmes are around 100.53
Currently, the implementation of PBM in 
Europe except for the Netherlands, Austria, and 
Spain is limited.55 PBM strategies are in place 
for major elective surgery in a limited number 
of hospitals in Switzerland,55 while in the UK 
some centres are now developing pilot studies 
on PBM.55 A multicentre PBM programme will 
also be implemented in Germany.53 In Italy, the 
National Blood Centre, has recently included 
the implementation of a PBM programme 
among the objectives of the 2012 national plan 
for blood and blood product self-sufficiency.57 
Recently the Patient Blood Management Eu-
in spine surgery).46 Unfortunately, this retro-
spective study was not able to provide data on 
long-term effects of PBM such as hospital LOS, 
postoperative complications, and costs. Moreo-
ver, post-operative haemoglobin data were not 
available for all the patients.
Further studies described the implementation 
of PBM in larger scale programmes developed 
in single or multiple hospitals. In 2008, a PBM 
programme was implemented in 23 Canadian 
hospitals and it involved education, autologous 
donation, cell salvage, and erythropoietin ad-
ministration. After 24 months, most hospitals 
had demonstrated decreased use of allogeneic 
blood and patients who did not receive alloge-
neic transfusions had significantly lower post-
operative infection rates (P<0.05) and hospital 
LOS (P<0.0001). In multivariate analysis, allo-
geneic transfusion was an independent predic-
tor for LOS. This study clearly showed that such 
programmes can be applied widely, effectively, 
and cost-effectively through centralised manage-
ment.47 More recently, the excellent results of 
hospital-wide PBMs were reported in Australia 
and in the USA.34, 48 The results of the USA 
hospital were “achieved through hospital-wide 
physician buy-in toward a restrictive transfu-
sion approach” and resulted in a 43% reduc-
tion in RBC units transfused per patient dis-
charged.48 Unfortunately, the authors were not 
able to determine the number of RBC units in 
each physician’s order and did not analyse pa-
tient outcomes pre- and post-PBM. The same 
consistent reduction of blood product usage was 
observed also in an Australian teaching hospital 
where, despite a 22% increase in admissions, the 
mean number of RBC, fresh-frozen plasma, and 
platelet units per admission showed 26%, 38%, 
and 16% reduction, respectively.34 In the same 
period, the mean hospital LOS for primary to-
tal knee arthroplasty decreased from 5.9 to 4.8 
days. Also in this study, other PBM effects were 
not analysed and the outcomes were “likely” im-
proved by reducing patient exposure to alloge-
neic blood transfusion. No randomized control-
led trial comparing relevant clinical outcomes 
in patients managed through comprehensive 
PBM programmes against those who were not 
has been carried out so far.42 Therefore, the PBM 
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tions should be prospectively monitored. These 
assessments are to be performed regularly based 
on the hospital information system, analysed in 
the PBM steering committee and reported back 
to the responsible physicians. Such a monitor-
ing and feedback system has been shown to be 
highly efficacious.34 Anaesthesiologists thus have 
a key role in PBM programmes but should not 
try to implement such programmes alone. Only 
the joint effort of all parties included allows 
long-term success.
Conclusions
All treatments should be assessed for their ef-
fect on improving patients’ outcomes. Despite 
widespread use, allogeneic blood transfusions 
have not undergone such scrutiny and the bal-
ance between their established risks and ques-
tionable benefits is often overshadowed by a 
quest to meet arbitrary laboratory thresholds. 
The result is a transfusion practice that is highly 
variable, costly and likely to do more harm than 
good to the patients. Safety and efficacy con-
cerns of allogeneic blood transfusions and their 
impact on patient outcomes, together with stag-
gering costs and restricted supply, have fuelled 
the search for new modalities and strategies to 
reduce use of blood components. PBM focuses 
on multidisciplinary and multimodal preventive 
measures to reduce or obviate the need for trans-
fusions and ultimately to improve the clinical 
outcomes of patients through strategies that can 
be applied at every stage of care to surgical and 
non-surgical patients. Although the safety and 
efficacy of the different modalities used in PBM 
should be evaluated individually, emerging data 
support that PBM is safe and effective in pro-
viding better care and improving patients’ out-
comes while reducing transfusion of allogeneic 
blood components. Therefore, as perioperative 
medicine leaders, Anaesthesiologists are called to 
hold a key role in promoting, implementing and 
auditing PBM programmes at their institutions 
also introducing quality indexes for PBM such 
as the recently proposed percentage haematocrit 
variation index, which reflects haematocrit vari-
ations during 7 days of hospital stay in cardiac 
surgery patients.64
rope (PaBloE) Consortium, coordinated by the 
European Blood Alliance (EBA), was founded. 
It includes Denmark, Germany, Malta, Sweden, 
the Netherlands, and the UK, and Italy. Finally, 
a recent call for tender on good practices in the 
field of blood transfusion issued by the Euro-
pean Commission launched three objectives: 
1) develop a European PBM guide for Member 
States; 2) implement PBM programmes in 5 
teaching hospitals in European Member States; 
3) prepare strategies to help national authorities 
to disseminate and implement PBM across Eu-
rope.58
PBM: role of the anesthesiologist
In many hospitals anaesthesiologists in recent 
years gradually developed into peri-operative 
care specialists and therefore are in particularly 
well-suited position to lead multidisciplinary 
and multi-professional PBM programmes. Lead-
ership is key in the implementation and mainte-
nance of a PBM programme but the implemen-
tation can only be successful with the buy-in 
of all major surgical disciplines, haematology, 
blood banking and the Board of Directors of 
the hospital. Once a PBM steering committee 
has been founded, it is to issue hospital wide 
compulsory PBM guidelines and a continuous 
educational programme in which all included 
disciplines participate. The PBM guidelines are 
to define the main processes including rules that 
patients are being seen as early as possible, ide-
ally 30 days prior to elective surgery, to detect 
anaemia and to have sufficient time to specifical-
ly treat anemia if present. However, also short-
term treatment can be successful in orthopedic 59 
and cardiac surgery.60, 61 Also the introduction 
of blood sparing surgical techniques,41 the use of 
cell salvage 62 and transfusion guidelines issued 63 
are to be regulated by such PBM guidelines. But 
guidelines alone are not sufficient. A continuous 
monitoring system is to be introduced assessing 
the adherence to the guidelines. Issues to be as-
sessed are percentage of anemic patients operat-
ed, use of cell salvage, perioperative transfusion 
rate, and hemoglobin concentration at transfu-
sion. Ideally, also clinical outcomes such as infec-
tions, hospital LOS and thrombotic complica-
              COPYRIGHT© 2015 EDIZIONI MINERVA MEDICA 
Th
is
 d
oc
um
en
t i
s 
pr
ot
ec
te
d 
by
 in
te
rn
a
tio
na
l c
op
yr
ig
ht
 la
w
s.
N
o 
ad
di
tio
na
l r
ep
ro
du
ct
io
n 
is 
au
th
or
ize
d.
It 
is
 p
er
m
itt
ed
 fo
r 
pe
rs
on
al
 u
se
 to
 d
ow
n
lo
ad
 a
nd
 s
av
e
 o
n
ly 
on
e 
file
 a
nd
 p
rin
t o
nl
y 
on
e 
co
py
 o
f t
hi
s 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 m
ak
e
 a
dd
itio
na
l c
op
ie
s
(ei
the
r s
po
rad
ica
lly
 o
r s
ys
te
m
at
ica
lly
,
 
e
ith
er
 p
rin
te
d 
or
 e
le
ct
ro
ni
c) 
of 
the
 A
rtic
le
 fo
r 
a
ny
 p
ur
po
se
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 d
ist
rib
u
te
 th
e 
el
ec
tro
ni
c 
co
py
 o
f t
he
 a
rti
cl
e 
th
ro
ug
h 
on
lin
e 
in
te
rn
e
t a
nd
/o
r i
nt
ra
n
e
t f
ile
 s
ha
rin
g 
sy
st
em
s,
 
e
le
ct
ro
ni
c 
m
ai
lin
g 
or
 a
ny
 o
th
er
m
e
a
n
s 
w
hi
ch
 m
ay
 a
llo
w
 a
cc
e
ss
 to
 th
e 
Ar
tic
le
.
Th
e 
us
e 
of
 a
ll 
or
 a
ny
 p
ar
t o
f t
he
 A
rti
cl
e 
fo
r 
a
ny
 C
om
m
er
cia
l U
se
 is
 n
ot
 p
er
m
itt
ed
.T
he
 c
re
at
io
n 
of
 d
er
iva
tiv
e
 w
o
rk
s 
fro
m
 th
e 
Ar
tic
le
 is
 n
ot
 p
er
m
itt
ed
.T
he
 p
ro
du
ct
io
n 
of
 re
pr
in
ts
 fo
r 
pe
rs
on
al
 o
r c
om
m
er
cia
l u
se
 is
n
o
t p
er
m
itt
ed
.I
t i
s 
no
t p
er
m
itt
ed
 to
 re
m
ov
e,
 
co
ve
r,
 
ov
e
rla
y, 
o
bs
cu
re
,
 
bl
oc
k,
 o
r c
ha
ng
e 
an
y 
co
py
rig
ht
 n
ot
ice
s 
or
 te
rm
s 
o
f u
se
 w
hi
ch
 th
e 
Pu
bl
is
he
r m
ay
 p
os
t o
n 
th
e 
Ar
tic
le
.
It 
is
 n
ot
 p
er
m
itt
ed
 to
 fr
a
m
e
 o
r 
u
se
 fr
a
m
in
g 
te
ch
ni
qu
es
 to
 e
nc
lo
se
 a
ny
 tr
a
de
m
ar
k,
 lo
go
,
o
r 
o
th
er
 p
ro
pr
ie
ta
ry
 in
fo
rm
a
tio
n 
of
 th
e 
Pu
bl
is
he
r.
PATIENT BLOOD MANAGEMENT LIUMBRUNO
Vol. 81 - No. 10 MINERVA ANESTESIOLOGICA 1135
base on Anaemia. Geneva, Switzerland: World Health Or-
ganization Press; 2008 [Internet]. Available from: http://
whqlibdoc.who.int/publications/2008/9789241596657_
eng.pdf [cited 2014, Aug 16].
 8. Shander A, Knight K, Thurer R, Adamson J, Spence R. 
Prevalence and outcomes of anemia in surgery: a systematic 
review of the literature. Am J Med 2004;116:58S-69S.
 9. Spahn DR. Anemia and patient blood management in hip 
and knee surgery: a systematic review of the literature. An-
esthesiology 2010;113:482-95.
10. Bisbe E, Castillo J, Sáez M, Santiveri X, Ruíz A, Muñoz 
M. Prevalence of preoperative anemia and hematinic defi-
ciencies in patients scheduled for elective major orthopedic 
surgery. Transfus Alternat Transfus Med 2008;10:166-73.
11. Musallam KM, Tamim HM, Richards T, Spahn DR, 
Rosendaal FR, Habbal A et al. Preoperative anaemia and 
postoperative outcomes in non-cardiac surgery: a retrospec-
tive cohort study. Lancet 2011;378:1396-407.
12. Jans O, Jørgensen C, Kehlet H, Johansson PI; Lundbeck 
Foundation Centre for Fast-track Hip and Knee Replace-
ment Collaborative Group. Role of preoperative anemia for 
risk of transfusion and postoperative morbidity in fast-track 
hip and knee arthroplasty. Transfusion 2014;54:717-26.
13. Basora M, Tió M, Martin N, Lozano L, Salazar F, Sánchez-
Etayo G et al. Should all patients be optimized to the same 
preoperative hemoglobin level to avoid transfusion in pri-
mary knee arthroplasty? Vox Sang 2014 [Epub ahead of 
print].
14. Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, 
Rossetti G, Italian Society of Transfusion Medicine and Im-
munohaematology (SIMTI) Working Party. Recommen-
dations for the transfusion management of patients in the 
peri-operative period. I. The pre-operative period. Blood 
Transfus 2011;9:19-40.
15. Koch CG, Li L, Sun Z, Hixson ED, Tang A, Phillips SC 
et al. Hospital-acquired anemia: Prevalence, outcomes, and 
healthcare implications. J Hosp Med 2013;8:506-12.
16. Liumbruno GM, Grazzini G. Double bull’s eye for post-op-
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reduces blood loss and transfusion rates in total hip and 
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20. Tan J, Chen H, Liu Q, Chen C, Huang W. A meta-analy-
sis of the effectiveness and safety of using tranexamic acid 
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2013;184:880-7.
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blood salvage in patient blood management: is it really cost-
effective and safe? Blood Transfus 2013;11:175-7.
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26. Salpeter SR, Buckley JS, Chatterjee S. Impact of more 
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Key messages
 — Blood transfusions are risky, costly and the 
supply of blood is limited. Blood transfusion out-
comes are therefore undergoing renewed scrutiny 
by healthcare institutions to reduce blood utiliza-
tion.
 — Patient blood management is an evidence-
based, multidisciplinary, multimodal, and pa-
tient-tailored approach aimed at reducing or 
eliminating the need for allogeneic transfusion. 
These objectives can be reached through the so-
called three pillars of Patient blood management: 
a) optimising the patient’s erythropoiesis; b) 
minimising bleeding and c) harnessing and op-
timising the patient-specific physiological reserve 
of anemia.
 — Emerging data support that patient blood 
management is safe and effective in providing 
better care and improving patients’ outcomes 
while reducing transfusion of allogeneic blood 
component
 — As perioperative medicine leaders, an-
esthesiologists hold a key role in promoting, im-
plementing and auditing PBM programmes at 
their institutions.
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